MedTrace Logo

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

NCT04735263 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-01-26

No results posted yet for this study

Summary

interventional trial for off label use of high dose atorvastatin 80 mg in intermediate AMD patients and correlate recovery response measured by dark adaptation recovery time with drusen volume reduction measured by SD-OCT

Conditions

  • Age-related Macular Degeneration

Interventions

DRUG

Atorvastatin 80mg

Patient will be receiving 80mg of Atorvastatin, if they are able to tolerate it from the start to the end of the study.

Sponsors & Collaborators

  • Massachusetts Eye and Ear Infirmary

    lead OTHER

Principal Investigators

  • John B Miller, MD · Massachusetts Eye and Ear Infirmary, Harvard Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-04
Primary Completion
2027-04-01
Completion
2028-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04735263 on ClinicalTrials.gov